IN8bio, Inc. INAB
1.20
0.01
0.84%
as of 25 Sep
- Market cap
- $11.1M
- P/E
- 0.0×
Follow INAB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
8.21 | 10.50 | 8.82 | 6.91 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.01 | 4.60 | 6.00 | 3.09 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.38% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.97 | 0.43 | 0.91 | |
Capex/Depreciation |
(0.51) | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.20) | (0.25) | (0.49) | (0.78) | |
Cash per Share |
0.92 | 1.13 | 6.19 | 2.36 | |
Shareholders Equity per Share |
0.94 | 1.17 | 6.30 | 2.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.94 | 1.17 | 6.30 | 2.91 | |
Free Cash Flow |
(3.98) | (4.96) | (2.14) | (3.52) | |
Working Capital |
16.24 | 20.50 | 24.72 | 10.07 | |
Capital Expenditures |
(0.23) | (0.01) | — | — | |
Net Current Asset Value |
15.11 | 19.18 | 23.16 | 8.19 | |
| Other line items | |||||
Quick Ratio |
7.97 | 10.17 | 8.57 | 6.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.19) | (0.25) | (0.49) | (0.78) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.41 | 0.51 | 0.35 | 0.67 | |
Average Assets |
20.56 | 23.07 | 26.61 | 16.37 | |
Average Common Equity |
16.80 | 18.33 | 21.02 | 10.89 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates